Q4 2025 Harrow Inc Earnings Call Transcript
Key Points
- Harrow Inc (HROW) has undergone a significant transformation over the past five years, acquiring a large portfolio of ophthalmic products and achieving a 700% increase in stock price.
- The company reported strong financial performance in 2025, with a 33% year-over-year revenue growth in Q4 and a 36% increase for the full year.
- Harrow Inc (HROW) is expanding its sales force for key products like VEVYE and TRIESENCE, aiming to drive higher prescription volumes and revenue growth.
- The company is strategically positioned in the ophthalmic market with a diversified portfolio and a focus on expanding patient access and improving affordability.
- Harrow Inc (HROW) is advancing its pipeline with promising products like G-MELT, which has the potential to redefine procedural sedation and become a major revenue driver.
- The company faces risks and uncertainties related to FDA approval of certain drug candidates and the ability to make products commercially available.
- Harrow Inc (HROW) anticipates a softer first half of 2026 due to channel inventory drawdowns and seasonal deductible dynamics.
- The expiration of IHEEZO's pass-through status in the ASC market could impact revenue, although the company is working to offset this through in-office procedure expansion.
- The company is increasing SG&A expenses significantly to support sales force expansion and product launches, which could impact short-term profitability.
- There are challenges in converting compounded utilization into FDA-approved branded products, which requires strategic planning and execution.
Good day, and welcome to the Harrow fourth-quarter 2025 earnings conference call. (Operator Instructions) Please note that this call may be recorded.
I would now like to turn the call over to Mike Biega, Vice President, Investor Relations and Communications, please go ahead.
Good morning, and welcome to Harrow's fourth-quarter and full year 2025 earnings conference call. My name is Mike Biega, Vice President of Investor Relations and Communications, and I'm excited to be introducing today's call.
The company's remarks may include forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Harrow's control, including risks and uncertainties described from time to time in its SEC filings, such as the risks and uncertainties related to the company's ability to make commercially available its FDA-approved products and compounded formulations and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
